Abstract
Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity, with oncogenic KRAS/MAPK/ERK signaling arising from activating KRAS mutations being the key feature of this malignancy. Dysregulation of RNA polymerase II (Pol II)–dependent transcription is a universal hallmark of cancers, including PDAC, with aberrant gene expression programs driving tumorigenesis and influencing therapy response. Pol II progression through multiple transcription cycle checkpoints depends on transcriptional cyclin-dependent kinases (tCDK), and targeted inhibition of distinct tCDKs has been shown to be a promising anticancer strategy. In this study, we profile biological and molecular PDAC cell responses to selective blockade of tCDK kinase activity at all Pol II transcription cycle checkpoints, alone and in combination with inhibitors of mutant KRAS or MEK. We identify post–transcription-initiation checkpoints controlled by CDK9, CDK11, and CDK12/13 as critical for nascent gene expression and cell proliferation in PDAC. However, although dual targeting of tCDK and KRAS/MAPK/ERK networks amplifies transcriptomic phenotypes, this results in limited cooperative therapeutic impacts.
Funding Information
  • PanKind, The Australian Pancreatic Cancer Foundation (23.R9.NTG.RJ.UMEL.3)
  • National Health and Medical Research Council (2012371)
  • National Health and Medical Research Council
  • Worldwide Cancer Research (24-0129)
  • Leukemia and Lymphoma Society
  • Kids' Cancer Project
  • Barrie Dalgleish Centre for Myeloma and Associated Blood Diseases